# Pre-emptive Anakinra for Cytokine Event Reduction

> **NCT06703216** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago** · enrollment: 24 (estimated)

## Conditions studied

- B-Acute Lymphoblastic Leukemia
- CAR-T Cell Therapy
- Cytokine Release Syndrome
- Immune Effector Cell Associated Neurotoxicity Syndrome
- Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome

## Interventions

- **DRUG:** Anakinra (Kineret®)

## Key facts

- **NCT ID:** NCT06703216
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2029-08-31
- **Final completion:** 2030-02-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703216, "Pre-emptive Anakinra for Cytokine Event Reduction". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06703216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*